Login to Your Account

Hopes not vain for Revance wrinkle shots

By Randy Osborne
Staff Writer

Tuesday, December 5, 2017

RT-002 achieved "a trifecta of positive clinical results," Revance Therapeutics Inc. CEO Dan Browne said, pointing to across-the-board success in a pair of phase III trials with next-generation neuromodulator DaxibotulinumtoxinA for injection (RT-002).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription